Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
Assembly Biosciences (ASMB) had its price target raised by Guggenheim from $39.00 to $43.00. They now have a "buy" rating on the stock.
Assembly Biosciences (ASMB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights [Yahoo! Finance]